Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-13 5:08 pm Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | VANGUARD GROUP INC | 9,094,302 9.45% | 775,053 (+9.32%) | View |
| 2024-02-09 12:40 pm Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WASATCH ADVISORS LP | 3,627,308 3.8% | -1,112,837 (-23.48%) | View |
| 2024-02-09 09:16 am Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | FMR LLC | 11,457,694 11.905% | -571,095 (-4.75%) | View |
| 2024-02-08 10:14 am Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WELLINGTON MANAGEMENT GROUP LLP | 1,763,475 1.83% | -3,646,210 (-67.40%) | View |
| 2024-01-25 1:48 pm Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | BlackRock Inc. BLK | 8,192,987 8.5% | 743,458 (+9.98%) | View |
| 2023-02-09 11:22 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | VANGUARD GROUP INC | 8,319,249 8.78% | 1,443,048 (+20.99%) | View |
| 2023-02-09 11:18 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | FMR LLC | 12,028,789 12.701% | 1,066,820 (+9.73%) | View |
| 2023-02-06 2:53 pm Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WELLINGTON MANAGEMENT GROUP LLP | 5,409,685 5.71% | 5,409,685 (New Position) | View |
| 2023-02-03 4:27 pm Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | BlackRock Inc. BLK | 7,449,529 7.9% | 1,727,763 (+30.20%) | View |
| 2023-01-10 2:38 pm Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WASATCH ADVISORS LP | 4,740,145 5.01% | -3,495,623 (-42.44%) | View |
| 2022-02-10 1:38 pm Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WASATCH ADVISORS LP | 8,235,768 10.1% | -83,444 (-1.00%) | View |
| 2022-02-10 08:17 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | VANGUARD GROUP INC | 6,876,201 8.44% | 394,857 (+6.09%) | View |
| 2022-02-09 09:19 am Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | FMR LLC | 10,961,969 13.456% | -1,061,615 (-8.83%) | View |
| 2022-02-03 4:41 pm Sale | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | BlackRock Inc. BLK | 5,721,766 7% | -176,802 (-3.00%) | View |
| 2021-12-02 11:31 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WASATCH ADVISORS LP | 8,319,212 10.2% | 1,985,312 (+31.34%) | View |
| 2021-02-12 5:18 pm Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | BB BIOTECH AG | 3,538,419 4.4% | 80,000 (+2.31%) | View |
| 2021-02-10 11:03 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | VANGUARD GROUP INC | 6,481,344 8.09% | 2,261,754 (+53.60%) | View |
| 2021-02-09 3:23 pm Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | WASATCH ADVISORS LP | 6,333,900 7.9% | 6,333,900 (New Position) | View |
| 2021-02-08 10:25 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | FMR LLC | 12,023,584 14.999% | 5,698,929 (+90.11%) | View |
| 2021-01-29 09:57 am Purchase | 13G | INTRA-CELLULAR THERAPIES INC. ITCI | BlackRock Inc. BLK | 5,898,568 7.4% | 1,988,057 (+50.84%) | View |